Vaccine for Triple Negative Breast Cancer Looks Promising in Trial

G. Thomas Budd standing in a lab

It's Breast Cancer Awareness Month and G. Thomas Budd, MD, member of Case CCC's Immune Oncology Program, is getting noticed as the PI for his contribution to the vaccine created to find and attack the protein alpha-lactalbumin, an indicator of triple-negative breast cancer if found in women who are not lactating. The vaccine is based on 20 years of research by Budd and Vincent Tuohy (Case CCC member who passed away in January 2023). The human phase of the trials began in 2021. The data shows that most trial participants have generated robust immunity to the alpha-lactalbumin target even at the lowest tested dose.

Read More